NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 375
(Total Views: 201)
Posted On: 03/29/2023 4:06:03 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Virtual Investor Event
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor GBM Spotlight Event. The online event is scheduled for April 4, 2023, at 4:30 p.m. ET. The event will include a live, moderated video webcast with members of CNS Pharmaceuticals management, including CEO John Climaco; the panel will also include key opinion leader, Michael Weller, MD. Weller is an acclaimed neuro-oncologist who currently serves as chair of the Department of Neurology at the University Hospital in Zurich, Switzerland. He is also the national coordinating investigator for the current CNS Pharmaceuticals study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The focus of the panel’s discussion will be on the unmet need for treatment of GBM, one of the most aggressive types of brain cancer, as well as what CNS Pharmaceuticals is doing to advance Berubicin as a potential treatment. The event will be broadcast live on the company’s events page in the investor section of its website; a replay of the presentation will also be made available on the company website.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor GBM Spotlight Event. The online event is scheduled for April 4, 2023, at 4:30 p.m. ET. The event will include a live, moderated video webcast with members of CNS Pharmaceuticals management, including CEO John Climaco; the panel will also include key opinion leader, Michael Weller, MD. Weller is an acclaimed neuro-oncologist who currently serves as chair of the Department of Neurology at the University Hospital in Zurich, Switzerland. He is also the national coordinating investigator for the current CNS Pharmaceuticals study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The focus of the panel’s discussion will be on the unmet need for treatment of GBM, one of the most aggressive types of brain cancer, as well as what CNS Pharmaceuticals is doing to advance Berubicin as a potential treatment. The event will be broadcast live on the company’s events page in the investor section of its website; a replay of the presentation will also be made available on the company website.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)